UCB CEO Elected Vice President of the EFPIA Board
Brussels, 24 June 2013 - Today, UCB CEO and Chairman of the Executive Committee Roch Doliveux was elected Vice President of the EFPIA board. The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe.
In his role, Roch Doliveux will be looking to further spur innovation and collaboration among European biopharma companies, helping to bring forth new medicines that will improve the health and quality of life of patients.
For a full biography of Roch Doliveux, visit UCB's website.
For further information
France Nivelle, Global Communications, UCB
T +32.2.559.9178 , email@example.com
Laurent Schots, Media Relations, UCB
T +32.2.559.9264 , firstname.lastname@example.org
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 500 people in about 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).
Stay up-to-date on the latest news and information from UCB